Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial

John Glaspy,Igor Bondarenko,Dmitrii Krasnozhon,Dean Rutty,Jianmin Chen,Yanyan Fu,Shufang Wang,Qingsong Hou,Simon Li

DOI: https://doi.org/10.1007/s00520-023-08260-x

IF: 3.1

2024-01-10

Supportive Care in Cancer

Abstract:Evaluate the safety and efficacy of efbemalenograstim alfa for neutrophil support in breast cancer patients undergoing myelosuppressive chemotherapy in a phase 2, dose-finding, open-label study (NCT01648322, ClinicalTrials.gov, 2012–07-19).

oncology,health care sciences & services,rehabilitation

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the safety and efficacy of the new recombinant granulocyte - colony - stimulating factor (G - CSF), efbemalenograstim alfa, in providing neutrophil support during myelosuppressive chemotherapy in breast cancer patients. Specifically, the main objective of the study is to compare the non - inferiority of efbemalenograstim alfa with the existing standard drug pegfilgrastim in reducing the duration of moderate and severe neutropenia.

### Research Background

Chemotherapy - induced neutropenia is a common side effect, which increases the risk of infection and may lead to chemotherapy dose delay or reduction, thus affecting the treatment effect. Clinically, recombinant granulocyte - colony - stimulating factors (G - CSFs), such as filgrastim and pegfilgrastim, are usually used to shorten the time of neutropenia and reduce the risk of infection.

Efbemalenograstim alfa is a new recombinant G - CSF. It fuses human G - CSF with human IgG2 - Fc to form a dimer form. This drug is designed to be administered once per cycle and is intended to be a potential substitute for pegfilgrastim and may activate the G - CSF receptor more effectively.

### Research Objectives

The main objective of this clinical trial is to evaluate the efficacy and safety of three different doses of efbemalenograstim alfa (80 µg/kg, 240 µg/kg, 320 µg/kg) compared with pegfilgrastim (6 mg) in helping the recovery of absolute neutrophil count (ANC) after the first cycle of chemotherapy. Specific objectives include:

1. **Primary Efficacy Endpoint**: Evaluate the duration of moderate and severe neutropenia (ANC < 1.0 × 10^9/L) during the first cycle of chemotherapy.
2. **Secondary Efficacy Endpoint**: Evaluate the duration of moderate and severe neutropenia during the second to fourth cycles of chemotherapy, the duration of severe neutropenia (ANC < 0.5 × 10^9/L), the incidence of febrile neutropenia in each cycle, the time required to recover from the nadir to ANC ≥ 2.0 × 10^9/L, and the lowest ANC value in each cycle.
3. **Safety Assessment**: Evaluate adverse events (AEs), serious adverse events (SAEs), laboratory parameters (hematology, blood chemistry, and urinalysis), vital signs, electrocardiograms (ECGs), and physical examination results.

### Conclusion

Studies have shown that efbemalenograstim alfa has similar efficacy and safety to pegfilgrastim in reducing the duration of moderate and severe neutropenia. In the TAC chemotherapy regimen, different doses of efbemalenograstim alfa (240 µg/kg and 320 µg/kg) all show non - inferiority and may be superior to pegfilgrastim in some aspects.

Through this study, researchers hope to provide breast cancer patients with a new and effective neutrophil support option to reduce chemotherapy - related complications and improve treatment outcomes.